rs synthesis  (Biosynth Carbosynth)

Journal: Neuro-Oncology Advances

Article Title: Velcrin molecular glues induce apoptosis in glioblastomas with high PDE3A and SLFN12 expression

doi: 10.1093/noajnl/vdae115

Figure Lengend Snippet: Velcrin treatment reduces viability in glioblastoma models with high PDE3A and SLFN12 expression. (A) BAY 2666605 dose–response curves and IC 50 values of glioblastoma cell lines that are velcrin-sensitive. (B) Dose–response curves of glioblastoma cell lines that are velcrin-insensitive. (C) PDE3A and SLFN12 mRNA expression of glioblastoma cell lines that are velcrin-sensitive versus velcrin-insensitive. (D) Immunoblot showing PDE3A and SLFN12 protein expression in glioblastoma cell lines that are velcrin-sensitive and vecrin-insensitive. (E) Quantification of PDE3A and SLFN12 protein expression (normalized to GB1 cells) in glioblastoma cell lines that are velcrin-sensitive and velcrin-insensitive. (F) BAY 2666605 dose–response curves in normal human astrocytes, human bone marrow stem cells, and brain microvascular endothelial cells. (G) PDE3A and SLFN12 mRNA expression were obtained using microarrays in a panel of glioblastoma neurospheres from DFCI CPDM. (H) PDE3A and SLFN12 mRNA expression was obtained using RNA sequencing in a panel of glioblastoma neurospheres from Broad Institute CCLF. (I). Dose–response curve of BT288L treated with DNMDP and DNMDP with 100 nM trequinsin. (J) Dose–response curve of BT856 treated with DNMDP, BAY2666605, and DNMDP with 100 nM trequinsin. (K) Dose–response curve of BT294 treated with DNMDP, BAY 2666605, and MG132. (L) Dose–response curve of BT228 treated with DNMDP, BAY 2666605, and MG132. (M) Dose–response curve of BT359 treated with DNMDP, BAY 2666605, and MG132. *= P < .05, ***= P < .001, ****= P < .0001.

Article Snippet: After RNA extraction, library synthesis was performed using the TruSeq mRNA HT Synthesis Kit (Illumina, RS-122-2103).

Techniques: Expressing, Western Blot, RNA Sequencing

Journal: Neuro-Oncology Advances

Article Title: Velcrin molecular glues induce apoptosis in glioblastomas with high PDE3A and SLFN12 expression

doi: 10.1093/noajnl/vdae115

Figure Lengend Snippet: Velcrin treatment leads to tumor regression in vivo in glioblastoma PDX models. (A) Schema of the experimental approach to test velcrin activity in vivo in glioblastoma subcutaneous PDX models. (B) PDE3A and SLFN12 mRNA expression of glioblastoma PDX models. (C) Serial quantification of tumor volumes in animals harboring subcutaneous Glio11305 tumors treated with vehicle or twice daily doses of 5 mg/kg BAY 2666605. (D) Serial quantification of tumor volumes in animals harboring Glio12421 tumors treated with vehicle or twice daily doses of 40 mg/kg BRD3800. (E) Serial quantification of tumor volumes in animals harboring Glio11305 tumors treated with vehicle or twice daily doses of 40 mg/kg BRD3800. * = P < .05, *** = P < .001, **** = P < .0001.

Article Snippet: After RNA extraction, library synthesis was performed using the TruSeq mRNA HT Synthesis Kit (Illumina, RS-122-2103).

Techniques: In Vivo, Activity Assay, Expressing